Allergen-specific Immunoglobulin E (Dactylis glomerata) (sIgE (D. glomerata))

Allergen-specific Immunoglobulin E (IgE) recognizing Dactylis glomerata (Orchard grass) pollen allergens is a central component of the allergic immune response in sensitized individuals. These IgE antibodies are produced by plasma cells and bind with high affinity to FcεRI receptors on the surface of mast cells and basophils (Galli et al., Nature, 2008). Upon inhalation of Dactylis glomerata pollen, allergens such as Dac g 1 and Dac g 5 cross-link the IgE-FcεRI complexes, triggering the immediate release of inflammatory mediators like histamine and leukotrienes. This process leads to the clinical symptoms of allergic rhinitis, conjunctivitis, and asthma (WHO/IUIS Allergen Nomenclature). Therapeutic interventions include the monoclonal antibody Omalizumab, which binds to the Fc region of free IgE to prevent its interaction with receptors (National Library of Medicine, StatPearls). Additionally, allergen-specific immunotherapy (AIT) using Dactylis glomerata extracts works by inducing immune tolerance, characterized by the production of "blocking" IgG4 antibodies that compete with IgE for allergen binding (Moingeon, Clinical & Experimental Allergy, 2013). Monitoring serum levels of these specific IgE antibodies is crucial for diagnosing grass pollen allergy and assessing treatment efficacy.

Other names

Orchard grass-specific IgECocksfoot grass-specific IgEAnti-Dactylis glomerata IgEIgE specific for Dac g allergens

Neutralization of circulating IgE to prevent binding to FcεRI receptors on mast cells and basophils; induction of allergen-specific IgG4 blocking antibodies through immunotherapy.